Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice
Preprint
- 9 February 2022
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development of a large number of vaccines, several of which are now approved for use in humans. Understanding vaccine-elicited antibody responses against emerging SARS-CoV-2 variants of concern (VOC) in real time is key to inform public health policies. Serum neutralizing antibody titers are the current best correlate of protection from SARS-CoV-2 challenge in non-human primates and a key metric to understand immune evasion of VOC. We report that vaccinated BALB/c mice do not recapitulate faithfully the breadth and potency of neutralizing antibody responses against VOC, as compared to non-human primates or humans, suggesting caution should be exercised when interpreting data for this animal model.Keywords
Other Versions
- Published version: Version Cell Reports, 40, preprints
This publication has 25 references indexed in Scilit:
- Structure-based design of prefusion-stabilized SARS-CoV-2 spikesScience, 2020
- Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2Cell Host & Microbe, 2020
- Growth, detection, quantification, and inactivation of SARS-CoV-2Virology, 2020
- Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization AssaysViruses, 2020
- Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigenProceedings of the National Academy of Sciences of the United States of America, 2017
- Accurate design of megadalton-scale two-component icosahedral protein complexesScience, 2016
- Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative CrossPLoS Genetics, 2015
- Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccinesJournal of Virological Methods, 2010
- Acquisition of Complement Resistance through Incorporation of CD55/Decay-Accelerating Factor into Viral Particles Bearing Baculovirus GP64Journal of Virology, 2010
- Enzymatic assembly of DNA molecules up to several hundred kilobasesNature Methods, 2009